CWA Asset Management Group LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,368 shares of the medical research company’s stock after purchasing an additional 497 shares during the period. CWA Asset Management Group LLC’s holdings in Amgen were worth $2,647,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. TrimTabs Asset Management LLC grew its holdings in shares of Amgen by 88.9% in the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after acquiring an additional 288 shares during the period. American Beacon Advisors Inc. acquired a new stake in shares of Amgen in the 1st quarter worth approximately $106,000. Jackson Grant Investment Advisers Inc. grew its holdings in shares of Amgen by 0.8% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after acquiring an additional 5 shares during the period. Omnia Family Wealth LLC grew its holdings in shares of Amgen by 25.3% in the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after acquiring an additional 147 shares during the period. Finally, Grove Bank & Trust grew its holdings in shares of Amgen by 87.4% in the 2nd quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock worth $126,000 after acquiring an additional 341 shares during the period. Institutional investors own 78.32% of the company’s stock.

In related news, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The disclosure for this sale can be found here. Over the last quarter, insiders sold 7,050 shares of company stock valued at $1,239,673. 0.19% of the stock is owned by insiders.

A number of brokerages have commented on AMGN. Royal Bank Of Canada began coverage on Amgen in a report on Thursday, September 14th. They set a “sector perform” rating and a $192.00 target price on the stock. Bank of America increased their target price on Amgen to $210.00 and gave the company a “buy” rating in a report on Thursday, October 5th. Oppenheimer reiterated a “buy” rating and set a $203.00 target price on shares of Amgen in a report on Friday, October 6th. Mizuho reiterated a “buy” rating and set a $198.00 target price on shares of Amgen in a report on Friday, October 6th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $196.00 target price (up previously from $189.00) on shares of Amgen in a report on Friday, October 6th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $190.22.

Amgen Inc. (AMGN) opened at $177.20 on Monday. The company has a debt-to-equity ratio of 1.05, a current ratio of 6.07 and a quick ratio of 5.72. The firm has a market capitalization of $128,631.43, a price-to-earnings ratio of 14.09, a P/E/G ratio of 2.57 and a beta of 1.37. Amgen Inc. has a 52-week low of $138.83 and a 52-week high of $191.10.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the consensus estimate of $3.11 by $0.16. The business had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business’s quarterly revenue was down .7% on a year-over-year basis. During the same period last year, the company posted $3.02 EPS. analysts predict that Amgen Inc. will post 12.66 earnings per share for the current fiscal year.

Amgen announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s management believes its shares are undervalued.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Friday, November 17th will be issued a $1.15 dividend. The ex-dividend date is Thursday, November 16th. This represents a $4.60 annualized dividend and a yield of 2.60%. Amgen’s dividend payout ratio is currently 41.63%.

ILLEGAL ACTIVITY WARNING: “Amgen Inc. (AMGN) Holdings Boosted by CWA Asset Management Group LLC” was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/amgen-inc-amgn-holdings-boosted-by-cwa-asset-management-group-llc/1742246.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.